MARKET

AXSM

AXSM

Axsome
NASDAQ

Real-time Quotes | Nasdaq Last Sale

85.20
-2.56
-2.92%
After Hours: 85.49 +0.29 +0.34% 16:34 01/24 EST
OPEN
87.78
PREV CLOSE
87.76
HIGH
88.25
LOW
84.30
VOLUME
531.03K
TURNOVER
--
52 WEEK HIGH
109.94
52 WEEK LOW
7.63
MARKET CAP
3.14B
P/E (TTM)
-53.0676
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AXSM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AXSM News

  • Axsome (AXSM) Completes Patient Randomization in TRD Study
  • Zacks.1d ago
  • Axsome up 2% premarket on advancement of AXS-05
  • seekingalpha.2d ago
  • Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
  • GlobeNewswire.2d ago
  • ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why
  • Zacks.01/17 13:45

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About AXSM

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
More

Webull offers Axsome Therapeutics Inc (AXSM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.